Dynacure’s recent publication in ‘Neuromuscular Disorders’, co-authored with Dr Laurent Servais, Dr Jim Dowling and Dr Valérie Biancalana:

‘An integrated modelling methodology for estimating the prevalence of centronuclear myopathy’ 

This innovative modelling approach by Dynacure/ISMS resulted in the 1st peer reviewed study on quantification of the CNM patient population with a detailed analysis related to incidence/prevalence in function of severity, mutation, gender.

Vandersmissen et al., An integrated modelling methodology for estimating the prevalence of centronuclear myopathy, Neuromuscular Disorders (2018)


About Dynacure: www.dynacure.com 

Dynacure develops new treatments for patients suffering from serious orphan disorders. Dynacure’s lead program, Dyn101, is designed to address centronuclear myopathy (CNM), a rare and debilitating disease affecting children and young adults. The Dyn101 development program targets the Dynamin 2 protein using a cEt antisense oligonucleotide candidate developed in collaboration with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.

Dynacure was founded by Kurma Partners, SATT Conectus and Ionis Pharmaceuticals in 2016, based on foundational research conducted at the Institute of Genetic and Molecular and Cellular Biology (IGBMC) in Strasbourg.

About ISMS: www.ismsbelgium.be 

I.S.M.S. partners with research-oriented Pharma and Biotech companies aiming to support them in realizing Market Access with their innovations. ISMS uses a validated fact-based methodology identifying and collecting the evidence required to differentiate from comparators, demonstrate 2

cost-effectiveness, meeting payor requirements for acquiring premium price. ISMS focusses on orphan diseases, immunology and oncology.

ISMS was founded by Geert Vander Stichele in 1983. With MindBytes, its sister company, focusing on serious medical games it has partnerships with the Universities of Leuven, Ghent (Belgium) and Uppsala (Sweden) as well with Pharma industry through European private-public consortiums, such as PREFER.


NewCap – European Media Relations
Nicolas Merigeau
+33(0)1 44 71 94 98

Ten Bridge Communications – U.S. Media Relations
Tom Donovan
+1 857 559 3397

Stephane van Rooijen, CEO

Geert Vander Stichele, CEO